FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160309425> ?p ?o ?g. }

• W2160309425 endingPage "955" @default.
• W2160309425 startingPage "951" @default.
• W2160309425 abstract "The aim of the present study was to determine the relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors (SSRI) treatment on premature ejaculation. Sixty married men (aged 20–50) with lifelong premature ejaculation and forty healthy men (aged 24–48) as control group were included in this study. The patients were evaluated by intravaginal ejaculation latency time (IELT) for premature ejaculation (PE). IELT<1 min is accepted PE. Patients with diabetes mellitus, chronic disorders or erectile dysfunction and heavy smokers were excluded. All patients were evaluated with history, physical examination, International Index of Erectile Dysfunction-5 (IIEF-5) score and IELT by stopwatch method. Nitric oxide levels were measured by Griess reaction, and all samples were frozen at −80 °C. Patients were randomly categorised 4 group to receive fluoxetine 20 mg day−1 (Group 1), paroxetine 20 mg day−1 (Group 2), sertraline 50 mg day−1 (Group 3) and healthy control (Group 4) for 4 weeks. Baseline and post-treatment findings were compared between the four groups. At the end of 4 weeks, in fluoxetine, paroxetine, sertraline groups mean IELT values showed a statistically significant improvement from the baseline values (P < 0.001, P < 0.001, P = 0.03; respectively). Baseline and 1st month follow-up mean IIEF scores were 24.5 and 23.05, 24.70 and 23.60 (P < 0.05) in group 1 and group 3 respectively; also 23.09 and 23.32 (P > 0.05) in group 2. Baseline serum NO levels were 31.8, 30.44, 30.8 and 42.84 in fluoxetine, paroxetine, sertraline and healthy control groups respectively. NO levels were statistically lower in patients with PE. After treatment of fluoxetine, paroxetine and sertraline, NO levels were increased baseline (35.8, 36.4, 38.08) (P < 0.05). Our findings indicated that PE is associated with decreased serum NO levels. After the SSRI treatment increased, NO may retard ejaculation presumably by central peripheral mechanism. Further studies are needed to confirm this suggestion and the role of NO in pathophysiology and treatment for premature ejaculation." @default.
• W2160309425 created "2016-06-24" @default.
• W2160309425 creator A5028214285 @default.
• W2160309425 creator A5036307310 @default.
• W2160309425 creator A5037077835 @default.
• W2160309425 creator A5054251249 @default.
• W2160309425 creator A5068844739 @default.
• W2160309425 creator A5069092440 @default.
• W2160309425 creator A5087591568 @default.
• W2160309425 date "2013-10-11" @default.
• W2160309425 modified "2023-10-15" @default.
• W2160309425 title "Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation: decreased nitric oxide is associated with premature ejaculation" @default.
• W2160309425 cites W172650844 @default.
• W2160309425 cites W1976278728 @default.
• W2160309425 cites W1977830476 @default.
• W2160309425 cites W1986297843 @default.
• W2160309425 cites W1997858761 @default.
• W2160309425 cites W2000640050 @default.
• W2160309425 cites W2006539797 @default.
• W2160309425 cites W2016875631 @default.
• W2160309425 cites W2018675758 @default.
• W2160309425 cites W2023633744 @default.
• W2160309425 cites W2037108837 @default.
• W2160309425 cites W2038063468 @default.
• W2160309425 cites W2058554972 @default.
• W2160309425 cites W2067814588 @default.
• W2160309425 cites W2070486940 @default.
• W2160309425 cites W2084855296 @default.
• W2160309425 cites W2091297288 @default.
• W2160309425 cites W2091913930 @default.
• W2160309425 cites W2091998818 @default.
• W2160309425 cites W2094888146 @default.
• W2160309425 cites W2103416422 @default.
• W2160309425 cites W2130471373 @default.
• W2160309425 cites W2137898665 @default.
• W2160309425 cites W2472488542 @default.
• W2160309425 doi "https://doi.org/10.1111/and.12179" @default.
• W2160309425 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24118023" @default.
• W2160309425 hasPublicationYear "2013" @default.
• W2160309425 type Work @default.
• W2160309425 sameAs 2160309425 @default.
• W2160309425 citedByCount "13" @default.
• W2160309425 countsByYear W21603094252015 @default.
• W2160309425 countsByYear W21603094252016 @default.
• W2160309425 countsByYear W21603094252017 @default.
• W2160309425 countsByYear W21603094252019 @default.
• W2160309425 countsByYear W21603094252020 @default.
• W2160309425 countsByYear W21603094252021 @default.
• W2160309425 countsByYear W21603094252022 @default.
• W2160309425 countsByYear W21603094252023 @default.
• W2160309425 crossrefType "journal-article" @default.
• W2160309425 hasAuthorship W2160309425A5028214285 @default.
• W2160309425 hasAuthorship W2160309425A5036307310 @default.
• W2160309425 hasAuthorship W2160309425A5037077835 @default.
• W2160309425 hasAuthorship W2160309425A5054251249 @default.
• W2160309425 hasAuthorship W2160309425A5068844739 @default.
• W2160309425 hasAuthorship W2160309425A5069092440 @default.
• W2160309425 hasAuthorship W2160309425A5087591568 @default.
• W2160309425 hasBestOaLocation W21603094251 @default.
• W2160309425 hasConcept C11171543 @default.
• W2160309425 hasConcept C126322002 @default.
• W2160309425 hasConcept C15744967 @default.
• W2160309425 hasConcept C170493617 @default.
• W2160309425 hasConcept C2775864247 @default.
• W2160309425 hasConcept C2776134451 @default.
• W2160309425 hasConcept C2776768464 @default.
• W2160309425 hasConcept C2777669559 @default.
• W2160309425 hasConcept C2777812360 @default.
• W2160309425 hasConcept C2777828372 @default.
• W2160309425 hasConcept C2779177272 @default.
• W2160309425 hasConcept C2779892816 @default.
• W2160309425 hasConcept C2779929075 @default.
• W2160309425 hasConcept C2780092697 @default.
• W2160309425 hasConcept C2781161787 @default.
• W2160309425 hasConcept C31487548 @default.
• W2160309425 hasConcept C519581460 @default.
• W2160309425 hasConcept C71924100 @default.
• W2160309425 hasConceptScore W2160309425C11171543 @default.
• W2160309425 hasConceptScore W2160309425C126322002 @default.
• W2160309425 hasConceptScore W2160309425C15744967 @default.
• W2160309425 hasConceptScore W2160309425C170493617 @default.
• W2160309425 hasConceptScore W2160309425C2775864247 @default.
• W2160309425 hasConceptScore W2160309425C2776134451 @default.
• W2160309425 hasConceptScore W2160309425C2776768464 @default.
• W2160309425 hasConceptScore W2160309425C2777669559 @default.
• W2160309425 hasConceptScore W2160309425C2777812360 @default.
• W2160309425 hasConceptScore W2160309425C2777828372 @default.
• W2160309425 hasConceptScore W2160309425C2779177272 @default.
• W2160309425 hasConceptScore W2160309425C2779892816 @default.
• W2160309425 hasConceptScore W2160309425C2779929075 @default.
• W2160309425 hasConceptScore W2160309425C2780092697 @default.
• W2160309425 hasConceptScore W2160309425C2781161787 @default.
• W2160309425 hasConceptScore W2160309425C31487548 @default.
• W2160309425 hasConceptScore W2160309425C519581460 @default.
• W2160309425 hasConceptScore W2160309425C71924100 @default.
• W2160309425 hasIssue "9" @default.
• W2160309425 hasLocation W21603094251 @default.
• W2160309425 hasLocation W21603094252 @default.

• next